Introduction
Castration-resistant prostate cancer (CRPC) is defined by disease progression despite castrate levels of testosterone and may present as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre-existing disease, and/or the appearance of new metastases.
Advanced prostate cancer has been known under a few names over the years, including hormone-resistant prostate cancer (HRPC) and androgen-insensitive prostate cancer (AIPC). Most recently, the terms castration-resistant prostate cancer or castration-recurrent prostate cancer were introduced with the realization that extra-testicular androgen production plays a significant role in the resistance of prostate cancer cells to medical or surgical castration therapy. 1 In their second publication, the Prostate Cancer Working Group defined CRPC as a continuum on the basis of whether metastases are detectable (clinically or by imaging) and whether the serum testosterone is in the castrate range by surgical orchidectomy or medical therapy. 2 This definition creates a clinical-states model where patients can be classified. The rising prostatespecific antigen (PSA) states (castrate and non-castrate) signify that no detectable (measurable or non-measurable) disease has ever been found. The clinical metastases states (castrate and noncastrate) signify that disease was detectable at some point in the past, regardless of whether it is detectable now.
CRPC includes patients without metastases or symptoms with rising PSA levels despite androgen deprivation therapy (ADT) to patients with metastases and significant debilitation due to cancer symptoms.
Management of CRPC

First and second line hormonal agents
Because the androgen receptor remains active in most patients who have developed castration-resistant disease, it is recommended that ADT be continued for the remainder of a patient's life (Level 3, Grade C).
In patients who develop CRPC, secondary hormonal treatments may be attempted (Level 3, Grade C).
To this date, no study of secondary hormone treatment has shown survival benefits; most trials have been small and were not designed to evaluate overall survival and were heavily confounded by future treatments used. In patients treated with luteinizing hormone-releasing hormone (LHRH) agonist/antagonist monotherapy or who have had an orchidectomy, the addition of total androgen blockade (TAB) with androgen receptor antagonists, such as bicalutamide, can offer modest PSA responses that are short lived in 30% to 35% of patients. 4 For patients who have undergone TAB, the antiandrogen should be discontinued to test for an antiandrogen withdrawal response (AAWD). Introducing or changing antiandrogen (AA) or using corticosteroids with or without ketoconazole have been noted to cause transient PSA reductions in about 30% of patients (Level 3, Grade C).
Non-metastatic CRPC
There is no standard of care and no approved regimen in M0 CRPC. AA therapy should be discontinued if patients are receiving these agents. Secondary hormonal treatments may be attempted (Level 3, Grade C).
Detection of metastases and imaging
For patients who progress on ADT without evidence of distant metastases, it is suggested to screen for bone metastases with bone scans and monitor for lymph node and visceral metastases/progression with imaging of the abdomen/pelvis and chest.
Patients with a rapid PSA doubling time (PSADT (<8 months) are at risk for developing earlier metastases. Imaging in these patients should be performed every 3 to 6 months. Patients with a slower PSADT (>12 months) should be screened every 6 to 12 months (Expert Opinion). Imaging techniques most commonly used include nuclear bone scans and abdominal/pelvic computed tomography and chest X-ray. The role of magnetic resonance imaging and positronemission tomography are still unclear. 
Treatment of metastatic CRPC (mCPRC)
Currently
Abiraterone acetate
Abiraterone acetate is a potent and irreversible inhibitor of CYP-17, a critical enzyme in androgen biosynthesis.
Chemo Naïve Setting: Abiraterone acetetate 1000 mg/day plus prednisone 5 mg twice daily is recommended for first-line therapy for asymptomatic or minimally symptomatic metastatic CRPC (Level 1, Grade A).
In asymptomatic or minimally symptomatic patients (defined as pain that is relieved by acetaminophen or a non-steroidal anti-inflammatory) without visceral metastases, abiraterone acetate significantly improved radiographic progression free survival (PFS) (16.5 mos vs. 8.3 mos) (HR 0.53; 95% CI 0.45-0.62; P<0.001). Abiraterone also significantly delayed time to pain progression, time to chemotherapy initiation, time to opiate initiation and deterioration of the Eastern Cooperative Oncology Group (ECOG) performance status. There was a non-significant 5-month improvement in overall survival (OS) at the interim analysis. The final analysis of the study now confirms a statistically significant 4.4 months improvement in overall survival (HR 0.81 p=0.0033). In the post-docetaxel setting, abiraterone-prednisone compared to placebo-prednisone has significantly prolonged median overall survival (OS) by 4.6 months (15.8 vs. 11.2 months; hazard ratio (HR): 0.74; p = 0.0001) in patients with mCRPC who had progressed after docetaxel treatment. Moreover, all secondary endpoints provided support for the superiority of abiraterone over placebo; median time to PSA progression (8.5 vs. 6.6 months; HR: 0.63; p < 0.0001), radiographic progression-free survival (PFS) (5.6 vs. 3.6 months; HR: 0.66; p < 0.0001), confirmed PSA response rate defined as ≥ 50% reduction in PSA from the pretreatment baseline PSA (29% vs. 5.5%; p < 0.0001) and objective response by Response Evaluation Criteria in Solid Tumors (RECIST) (14.8% vs. 3.3%; p < 0.0001). 6 
Enzalutamide
Enzalutamide is a potent multi targeted androgen signalling pathway inhibitor.
Chemo Naïve Setting: Enzalutamide (160 mg per day) is recommended as first-line therapy for asymptomatic or minimally symptomatic metastatic CRPC (Level 1, Grade A).
In asymptomatic or minimally symptomatic patients (defined as pain that is relieved by acetaminophen or a non-steroidal anti-inflammatory), enzalutamide decreased the risk of radiographic progression or death by 81% (hazard ratio [HR], 0.19; 95% confidence interval [CI], 0.15 to 0.23; P<0.001) and the risk of death by 29% (HR, 0.71; 95% CI, 0.60 to 0.84; P<0.001) as compared with placebo. The benefit of enzalutamide was demonstrated for all secondary end points, including time to initiation of cytotoxic chemotherapy time to first skeletal-related event, best overall soft tissue response (59% vs. 5%; P<0.001), time to prostatespecific antigen (PSA) progression (HR 0.17; P<0.001), and ≥50% PSA decline rate (78% vs. 4%; P<0.001). Enzalutamide also significantly delayed time to pain progression, time to opiate initiation and deterioration of the ECOG performance status. In patients previously treated with docetaxel the AFFIRM trial compared enzalutamide and placebo. 8, 9 The study demonstrated a significant advantage in OS of 4.8 months (18.4 vs. 13.6 months; HR: 0.62; p < 0.0001) and all secondary end points, including confirmed PSA response rate (54% vs. 2%, p < 0.001), soft-tissue response rate (29% vs. 4%, p < 0.001), the time to PSA progression (8. PSA response rates were also statistically significantly higher with docetaxel compared to mitoxantrone. In the 2 trials, 27% (n = 412) and 29% (n = 196) of patients had measurable disease.
Although patients received up to 10 cycles of treatment if no progression and no prohibitive toxicities were noted, the duration of therapy should be based on the assessment of benefit and toxicities. Rising PSA only should not be used as the sole criteria for progression; assessment of response should incorporate clinical and radiographic criteria.
Alternative therapies that have not demonstrated improvement in overall survival, but can provide disease control, palliation and improve quality of life, include weekly docetaxel plus prednisone, and mitoxantrone plus prednisone (Level 2, Grade B).
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The timing of docetaxel therapy in men with evidence of metastases, but without symptoms, should be discussed with patients and therapy should be individualized based on patients' clinical status and preferences (Level 3, Grade C).
Use of estramustine in combination with other cytotoxic agents is not recommended due to the increased risk of clinically important toxicities. There is no evidence to support the use of this combination to improve survival or palliation (Level 2, Grade C).
For patients who do not respond to first-line ADT or who progress clinically or radiologically without significant PSA elevations may have neuroendocrine differentiation. Biopsy of accessible lesions should be considered to identify these patients; these patients should then be treated with combination chemotherapy, such as cisplatin/etoposide or carboplatin/etoposide (Level 3, Grade C).
Second-line systemic chemotherapy
Cabazitaxel is recommended for metastatic CRPC patients progressing on or following docetaxel (Level 1, Grade A).
A phase 3 study comparing cabazitaxel to mitoxantrone in patients previously treated with docetaxel has shown a statistically significant survival advantage. 13 This randomized, placebocontrolled trial recruited 755 docetaxel-pretreated CRPC patients. Overall survival was the primary endpoint of the study. Patients were randomized to receive prednisone 10 mg/day with 3-weekly mitoxantrone 12 mg/m 2 or cabazitaxel 25 mg/m 2 . An advantage in survival emerged in favour of the cabazitaxel group, with a median survival of 15.1 months compared with 12.7 months in the mitoxantrone group (HR 0.70; 95% CI 0.59, 0.83; p < 0.0001).
Other options
For patients who have had a good response to first line docetaxel re-treatment with docetaxel can be considered (Expert Opinion).
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Mitoxantrone may be considered a therapeutic option in symptomatic patients with mCRPC in the first or second line setting. Mitoxantrone has not shown any survival advantage but may give symptomatic relief. Of note in the second line setting it has limited activity and increased toxicity (Grade C).
III. Bone-targeted therapy a. Life-prolonging therapy
Radium-223
Radium-223 every 4 weeks for 6 cycles is recommended in patients with pain due to bone metastases and who do not have visceral metastases (Level 1, Grade A).
Radium-223 (previously known as alpharadin) is an intravenous alpha emitting agent that mimics calcium preferentially targeting bone metastases. In a randomized phase 3 study, radium-223 given every 4 weeks for 6 cycles compared to placebo. 17 Radium-223 demonstrated a significant improvement in overall survival and symptomatic skeletal related events. Overall survival was improved by 3.6 months (HR 0.7 p<0.0001) and skeletal-related events (SREs) were delayed by 5.8 months (p<0.0001). The study included patients with symptomatic bone metastases who were post docetaxel or ineligible for docetaxel. The study excluded patients with visceral metastases. PSA does not reflect patients who benefit however given the mechanism of action of the drug, alkaline phosphatase appears to be better marker of activity.
b. Supportive agents
Denosumab and zoledronic acid
In men with CRPC and bone metastases, denosumab (120 mg subcutaneous [SC]) or zoledronic acid (4 mg IV) every 4 weeks are recommended to prevent disease-related SREs, including pathological fractures, spinal cord compression, surgery or radiation therapy to bone (Level 1, Grade A).
Bone loss associated with ADT has been shown to increase the risk of fracture. [18] [19] [20] [21] [22] Moreover, about 90% of patients with metastatic CRPC will develop bone metastases, which cause local decreases in bone integrity. Patients are at significant risk of SREs that include pathological fractures, debilitating bone pain requiring palliative radiation therapy and spinal cord compression. Quality of life is affected by these complications.
Zoledronic acid is a third generation nitrogen containing bisphosphonate. Bisphosphonates other than zoledronic acid are not known to be effective to prevent disease-related SREs. In the placebo controlled zoledronic acid study fewer men receiving zoledronic acid had SREs (38% vs. 49% p = 0.02). 23 Zoledronic acid also increased the median time to first SRE (488 vs. 321 days, p = 0.01). There was an overall 36% reduction in the rate of SREs in treated patients. Treatment with zoledronic acid should not be used in men with baseline creatinine clearance <30 mL/min.
Denosumab is a fully humanized monoclonal antibody against RANK ligand. It has been shown to be effective in preventing bone loss and new vertebral fractures due to ADT. 22 In the setting of metastatic CRPC, denosumab (120 mg SC, every 4 weeks) compared to zoledronic acid (4 mg IV, every 4 weeks) has shown significant improvement in the time to the first SRE (20.7 vs. 17.1 months; p < 0.001 for non-inferiority; p = 0.008 for superiority), while OSand PFS were not different. 24 No dose modification for renal function is necessary in the case of denosumab; however, the risk of hypocalcaemia is increased and calcium monitoring and supplementation (with calcium and vitamin D) is recommended for both denosumab and zoeldronic acid. Denosumab has not been studied however in patients with severe renal impairment (GFR<30 ml/min).
Good oral hygiene, baseline dental evaluation for high-risk individuals and avoidance of invasive dental surgery during therapy are recommended to reduce risk of osteonecrosis of the jaw (ONJ) for patients treated with bone targeted therapies (Level 3, Grade C). [25] [26] [27] Zoledronic acid and denosumab have been used in combination with all the agents presently in use for the treatment of mCRPC. To date there have been no additional safety issues of concern that have been reported.
23,24
The optimal duration of zoledronic acid and denosumab in men with CRPC and bone metastases is undefined. The risk of ONJ appears to be related to time on bone targeted therapy, therefore caution should be taken in using these agents beyond 2 years.
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Denosumab and zoledronic acid are are not approved and not indicated for bone metastases prevention in Canada IV. Other supportive care therapies
Systemic corticosteroid therapy
Corticosteroid therapy with low dose prednisone or dexamethasone may also offer improvements in PSA values and/or palliative outcomes in up to 30% of patients in both symptomatic and asymptomatic men. Steroids may also exert an anti-neoplastic effect on prostate cancer (Level 3, Grade C).
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Palliative radiation
Bone metastases from prostate cancer are often radiosensitive and most men will experience partial or complete pain relief from external beam radiation to a specific lesion. Studies have shown that a single fraction of standard palliative radiotherapy (RT) is as effective as 5 or more fractions in providing palliation. However, more patients require retreatment for pain recurrence with single fraction radiation (Level 2, Grade B). Stereotactic body RT (SBRT) is a more precise and may be a more effective form of palliation delivered in 5 or fewer treatments and also may be considered (Level 3, Grade C).
Radionuclide therapy, in the form of systemic strontium-89 therapy, may be useful in the palliation of CRPC when multiple skeletal sites are involved in carefully selected patients. Risks include severe prolonged myelosuppression and transfusion dependence. Strontium-89 may be associated with a worse overall survival as compared to external beam radiotherapy. 31, 32 Malignant spinal cord compression is an oncologic emergency that requires immediate diagnosis, if suspected, with an MRI. Options for treatment are debulking surgery + RT, vertebrectomy with stabilization and RT, or RT + steroids (Level 1, Grade A).
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Conclusion
Advances in treatment for men with CRPC have improved survival and quality of life, but most, if not all, patients eventually succumb from their disease and better treatments are required. Several new agents are being studied in all states of CRPC and an increase in options is likely in the near future. 9, [25] [26] [27] [34] [35] [36] Because CRPC remains an incurable and ultimately fatal illness, inclusion of patients in clinical trials remains paramount.
Summary
Agents that have shown improvements in survival in mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents and palliative radiation continue to play an important role in the overall management of mCRPC. Given the complexity, variety and importance of optimizing the use of these agents, a multi-disciplinary team approach is highly recommended. Palliative radiation therapy should be considered in patients with pain
